{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:50:26Z","timestamp":1789606226737,"version":"build-2803163510"},"reference-count":248,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/202.625\/2019-BOLSA"],"award-info":[{"award-number":["E-26\/202.625\/2019-BOLSA"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E26\/010.002128\/2019"],"award-info":[{"award-number":["E26\/010.002128\/2019"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["307294\/2018-8"],"award-info":[{"award-number":["307294\/2018-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The potential to treat neurodegenerative diseases (NDs) of the major bioactive compound of green tea, epigallocatechin-3-gallate (EGCG), is well documented. Numerous findings now suggest that EGCG targets protein misfolding and aggregation, a common cause and pathological mechanism in many NDs. Several studies have shown that EGCG interacts with misfolded proteins such as amyloid beta-peptide (A\u03b2), linked to Alzheimer\u2019s disease (AD), and \u03b1-synuclein, linked to Parkinson\u2019s disease (PD). To date, NDs constitute a serious public health problem, causing a financial burden for health care systems worldwide. Although current treatments provide symptomatic relief, they do not stop or even slow the progression of these devastating disorders. Therefore, there is an urgent need to develop effective drugs for these incurable ailments. It is expected that targeting protein misfolding can serve as a therapeutic strategy for many NDs since protein misfolding is a common cause of neurodegeneration. In this context, EGCG may offer great potential opportunities in drug discovery for NDs. Therefore, this review critically discusses the role of EGCG in NDs drug discovery and provides updated information on the scientific evidence that EGCG can potentially be used to treat many of these fatal brain disorders.<\/jats:p>","DOI":"10.3390\/biom11050767","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T22:31:25Z","timestamp":1621549885000},"page":"767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-3964","authenticated-orcid":false,"given":"Priscila Baltazar","family":"Gon\u00e7alves","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21949-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Renn\u00f3","family":"Sodero","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21949-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4278-212X","authenticated-orcid":false,"given":"Yraima","family":"Cordeiro","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21949-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2020). 2020 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 16, 391\u2013460.","DOI":"10.1002\/alz.12068"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yacoubian, T.A. (2017). Neurodegenerative Disorders: Why Do We Need New Therapies?, Elsevier Inc.","DOI":"10.1016\/B978-0-12-802810-0.00001-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","article-title":"Multi-target approach for natural products in inflammation","volume":"19","author":"Koeberle","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4155\/fmc-2017-0294","article-title":"The polypharmacology of natural products","volume":"10","author":"Ho","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ejmech.2018.12.020","article-title":"Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD)","volume":"163","author":"Romeiro","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Martins, M., Silva, R., Pinto, M.M.M., and Sousa, E. (2020). Marine natural products, multitarget therapy and repurposed agents in Alzheimer\u2019s disease. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090242"},{"key":"ref_10","first-page":"1","article-title":"Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)","volume":"15","author":"Singh","year":"2016","journal-title":"Nutr. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-017-0145-6","article-title":"The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer\u2019s disease: An overview of pre-clinical studies and translational perspectives in clinical practice","volume":"12","author":"Cascella","year":"2017","journal-title":"Infect. Agent. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biopha.2015.12.013","article-title":"Protective role of epigallocatechin-3-gallate in health and disease: A perspective","volume":"78","author":"Chowdhury","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153316","DOI":"10.1016\/j.phymed.2020.153316","article-title":"The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer\u2019s disease animal model: A systematic review","volume":"79","author":"Zhang","year":"2020","journal-title":"Phytomedicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopha.2016.06.042","article-title":"Neurodegenerative disorders share common features of \u201closs of function\u201d states of a proposed mechanism of nervous system functions","volume":"83","author":"Vadakkan","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dugger, B.N., and Dickson, D.W. (2017). Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a028035"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pomier, K.M., Ahmed, R., and Melacini, G. (2020). Catechins as tools to understand the molecular basis of neurodegeneration. Molecules, 25.","DOI":"10.3390\/molecules25163571"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0077-5","article-title":"Protein misfolding in neurodegenerative diseases: Implications and strategies","volume":"6","author":"Sweeney","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","article-title":"A new era for understanding amyloid structures and disease","volume":"19","author":"Iadanza","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbpa.2018.05.018","article-title":"Therapeutic strategies for targeting neurodegenerative protein misfolding disorders","volume":"44","author":"Scannevin","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ijbiomac.2019.05.109","article-title":"Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation","volume":"134","author":"Zaman","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_22","first-page":"2019","article-title":"Editorial: Protein Misfolding and Spreading Pathology in Neurodegenerative Diseases","volume":"12","author":"Bellucci","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ritchie, D.L., and Barria, M.A. (2021). Prion diseases: A unique transmissible agent or a model for neurodegenerative diseases?. Biomolecules, 11.","DOI":"10.3390\/biom11020207"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrn1007","article-title":"Unfolding the role of protein misfolding in neurodegenerative diseases","volume":"4","author":"Soto","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69429-6","article-title":"EGCG impedes human Tau aggregation and interacts with Tau","volume":"10","author":"Sonawane","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nature08984","article-title":"Biodemography of human ageing","volume":"464","author":"Vaupel","year":"2010","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","article-title":"The World report on ageing and health: A policy framework for healthy ageing","volume":"387","author":"Beard","year":"2016","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/00207454.2017.1286339","article-title":"Protein aggregation, misfolding and consequential human neurodegenerative diseases","volume":"127","author":"Sami","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mroczko, B., Groblewska, M., and Litman-Zawadzka, A. (2019). The role of protein misfolding and tau oligomers (TauOs) in Alzheimer\u2019s disease (AD). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194661"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","article-title":"\u03b1-Synuclein misfolding and aggregation: Implications in Parkinson\u2019s disease pathogenesis","volume":"1867","author":"Mehra","year":"2019","journal-title":"Biochim. Biophys. Acta-Proteins Proteomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2019.00025","article-title":"Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis","volume":"12","author":"Prasad","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41576-018-0011-4","article-title":"Prions, prionoids and protein misfolding disorders","volume":"19","author":"Scheckel","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2525967","article-title":"Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications","volume":"2017","author":"Liu","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Singh, A., Kukreti, R., Saso, L., and Kukreti, S. (2019). Oxidative stress: A key modulator in neurodegenerative diseases. Molecules, 24.","DOI":"10.3390\/molecules24081583"},{"key":"#cr-split#-ref_40.1","doi-asserted-by":"crossref","unstructured":"Cenini, G., Lloret, A., and Cascella, R. (2019). Oxidative stress in neurodegenerative diseases: From a mitochondrial point of viewCenini, G., Lloret, A.","DOI":"10.1155\/2019\/2105607"},{"key":"#cr-split#-ref_40.2","doi-asserted-by":"crossref","unstructured":"Cascella, R. Oxidative stress in neurodegenerative diseases: From a mitochondrial point of view. Oxidative Medicine and Cellular Longevity. Oxid. Med. Cell. Longev., 2019.","DOI":"10.1155\/2019\/2105607"},{"key":"ref_41","first-page":"1","article-title":"Neuroinflammation as a common feature of neurodegenerative disorders","volume":"10","author":"Maccioni","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1039\/C6RA26737H","article-title":"Two decades of new drug discovery and development for Alzheimer\u2019s disease","volume":"7","author":"Liu","year":"2017","journal-title":"RSC Adv."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gabr, M.T., and Yahiaoui, S. (2020). Multitarget Therapeutics for Neurodegenerative Diseases. Biomed Res. Int., 2020.","DOI":"10.1155\/2020\/6532827"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4155\/fmc-2018-0249","article-title":"Multitarget-directed ligands for neurodegenerative diseases: Real opportunity or blurry mirage?","volume":"11","author":"Benchekroun","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Maramai, S., Benchekroun, M., Gabr, M.T., and Yahiaoui, S. (2020). Multitarget Therapeutic Strategies for Alzheimer\u2019s Disease: Review on Emerging Target Combinations. Biomed Res. Int., 2020.","DOI":"10.1155\/2020\/5120230"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rossi, M., Freschi, M., Nascente, L.D.C., Salerno, A., de Melo, S., Teixeira, V., Nachon, F., Chantegreil, F., Soukup, O., and Malaguti, M. (2021). Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer \u2019 s Disease. J. Med. Chem.","DOI":"10.1021\/acs.jmedchem.1c00048"},{"key":"ref_48","unstructured":"(2021, January 06). World Health Organization WHO - The top 10 causes of death. Available online: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-018-0107-y","article-title":"Alzheimer\u2019s disease hypothesis and related therapies","volume":"7","author":"Du","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"ref_50","first-page":"1","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","article-title":"New approaches for the treatment of Alzheimer\u2019s disease","volume":"29","author":"Fish","year":"2019","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium Oligomannate: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"ref_54","first-page":"1","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: The trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"ref_58","first-page":"44913","article-title":"Abnormal phosphorylation of the microtubule-associated protein \u03c4 (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer\u2019s disease","volume":"16","author":"Goedert","year":"1993","journal-title":"Trends Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/pin.12520","article-title":"Plaque formation and the intraneuronal accumulation of \u03b2-amyloid in Alzheimer\u2019s disease","volume":"67","author":"Takahashi","year":"2017","journal-title":"Pathol. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1515\/revneuro-2017-0063","article-title":"Amyloid toxicity in Alzheimer\u2019s disease","volume":"29","author":"Reiss","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer \u2019 s Disease: The Amyloid Cascade Hypothesis Published by: American Association for the Advancement of Science Alzheimer \u2019 s Disease: The Amyloid Cascade Hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"key":"ref_64","first-page":"385","article-title":"BACE failures lower AD expectations, again","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_65","first-page":"2019","article-title":"News in Brief: Innovative antidepressants arrive; Anti-amyloid failures stack up as Alzheimer antibody flops","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","article-title":"Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins","volume":"88","author":"Kayed","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Imbimbo, B.P., Ippati, S., and Watling, M. (2020). Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer\u2019s disease or should they be looking elsewhere?. Expert Opin. Drug Discov., 1\u201311.","DOI":"10.1080\/17460441.2020.1793755"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kreiser, R.P., Wright, A.K., Block, N.R., Hollows, J.E., Nguyen, L.T., Leforte, K., Mannini, B., Vendruscolo, M., and Limbocker, R. (2020). Therapeutic strategies to reduce the toxicity of misfolded protein oligomers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228651"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2015.00191","article-title":"Soluble amyloid-\u03b2 oligomers as synaptotoxins leading to cognitive impairment in Alzheimer\u2019s disease","volume":"9","author":"Ferreira","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-021-02099-x","article-title":"Interleukin-1\u03b2 mediates alterations in mitochondrial fusion\/fission proteins and memory impairment induced by amyloid-\u03b2 oligomers","volume":"18","author":"Batista","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"ref_75","first-page":"1","article-title":"Short-term air pollution exposure aggravates Parkinson\u2019s disease in a population-based cohort","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.biopha.2017.03.100","article-title":"Parkinson\u2019s disease and pesticides: A meta-analysis of disease connection and genetic alterations","volume":"90","author":"Ahmed","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijheh.2018.12.006","article-title":"Air pollution and Parkinson\u2019s disease: A systematic review and meta-analysis up to 2018","volume":"222","author":"Kasdagli","year":"2019","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson\u2019s disease","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2018.00612","article-title":"Parkinson\u2019s disease: Biomarkers, treatment, and risk factors","volume":"12","author":"Emamzadeh","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.neurol.2019.11.002","article-title":"Parkinson\u2019s disease: From bench to bedside","volume":"176","author":"Draoui","year":"2020","journal-title":"Rev. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd.2018.136","article-title":"Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs","volume":"17","author":"Charvin","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.parkreldis.2017.07.020","article-title":"The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future","volume":"46","author":"Fahn","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.mpmed.2020.06.001","article-title":"Parkinson\u2019s disease","volume":"48","author":"Worth","year":"2020","journal-title":"Medicine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JPD-202128","article-title":"Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2020","volume":"10","author":"McFarthing","year":"2020","journal-title":"J. Parkinsons. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"a -Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"\u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson\u2019s disease - Lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Burtscher","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The role of \u03b1-synuclein oligomers in parkinson\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228645"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Boi, L., Pisanu, A., Palmas, M.F., Fusco, G., Carboni, E., Casu, M.A., Satta, V., Scherma, M., Janda, E., and Mocci, I. (2020). Modeling Parkinson\u2019s disease neuropathology and symptoms by intranigral inoculation of preformed human \u03b1-synuclein oligomers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228535"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.trechm.2019.04.009","article-title":"Challenges and Opportunities in Central Nervous System Drug Discovery","volume":"1","author":"Danon","year":"2019","journal-title":"Trends Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-cellbio-040320-120625","article-title":"Developing Therapies for Neurodegenerative Disorders: Insights from Protein Aggregation and Cellular Stress Responses","volume":"36","author":"Mallucci","year":"2020","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Imbimbo, B.P., Ippati, S., Watling, M., Balducci, C., Imbimbo, B.P., Ippati, S., Watling, M., Balducci, C., Imbimbo, B.P., and Ippati, S. (2021). Expert Opinion on Drug Discovery Accelerating Alzheimer \u2019 s disease drug discovery and development: What \u2019 s the way forward ? Accelerating Alzheimer \u2019 s disease drug discovery and development: What \u2019 s the way. Expert Opin. Drug Discov., 1\u20139.","DOI":"10.1080\/17460441.2021.1887132"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3233\/JAD-179921","article-title":"Multifactorial Hypothesis and Multi-Targets for Alzheimer\u2019s Disease","volume":"64","author":"Gong","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.drudis.2019.05.003","article-title":"The current status of pharmacotherapy for the treatment of Parkinson\u2019s disease: Transition from single-target to multitarget therapy","volume":"24","author":"Cheong","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Albertini, C., Salerno, A., de Sena, P., Pinheiro, M., and Bolognesi, M.L. (2020). From combinations to multitarget-directed ligands: A continuum in Alzheimer \u2019 s disease polypharmacology. Med. Res. Rev., 28.","DOI":"10.1002\/med.21699"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Khan, A., Jahan, S., Imtiyaz, Z., Alshahrani, S., Makeen, H.A., Alshehri, B.M., Kumar, A., Arafah, A., and Rehman, M.U. (2020). Neuroprotection: Targeting multiple pathways by naturally occurring phytochemicals. Biomedicines, 8.","DOI":"10.3390\/biomedicines8080284"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Romano, B., Lucariello, G., and Capasso, R. (2021). Topical Collection \u201cPharmacology of Medicinal Plants\u201d. Biomolecules, 11.","DOI":"10.3390\/biom11010101"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuint.2015.11.001","article-title":"Neurodegenerative diseases: From available treatments to prospective herbal therapy","volume":"95","author":"Solanki","year":"2016","journal-title":"Neurochem. Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4103\/1673-5374.205108","article-title":"Effects of medicinal plants on Alzheimer\u2019s disease and memory deficits","volume":"12","author":"Akram","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.biopha.2017.05.137","article-title":"Important medicinal herbs in Parkinson\u2019s disease pharmacotherapy","volume":"92","author":"Srivastav","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01555","article-title":"Plant Extracts and Phytochemicals Targeting \u03b1-Synuclein Aggregation in Parkinson\u2019s Disease Models","volume":"9","author":"Javed","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/13880209.2019.1618344","article-title":"Phytotherapy in treatment of Parkinson\u2019s disease: A review","volume":"57","author":"Rabiei","year":"2019","journal-title":"Pharm. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom11040543","article-title":"Neuroprotective herbs for the management of Alzheimer\u2019s disease","volume":"11","author":"Gregory","year":"2021","journal-title":"Biomolecules"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural Products as Sources of New Drugs over the Nearly Four Decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sharifi-Rad, M., Lankatillake, C., Dias, D.A., Docea, A.O., Mahomoodally, M.F., Lobine, D., Chazot, P.L., Kurt, B., Boyunegmez Tumer, T., and Catarina Moreira, A. (2020). Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041061"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Pohl, F., and Lin, P.K.T. (2018). The potential use of plant natural products and plant extracts with antioxidant properties for the prevention\/treatment of neurodegenerative diseases: In vitro, in vivo and clinical trials. Molecules, 23.","DOI":"10.3390\/molecules23123283"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Cardoso, S.M. (2019). Special issue: The antioxidant capacities of natural products. Molecules, 24.","DOI":"10.3390\/molecules24030492"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Thapa, A., and Carroll, N.J. (2017). Dietary modulation of oxidative stress in Alzheimer\u2019s disease. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071583"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Poga\u010dnik, L., Ota, A., and Poklar Ulrih, N. (2020). An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. Cells, 9.","DOI":"10.3390\/cells9030576"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Hano, C., and Tungmunnithum, D. (2020). Plant Polyphenols, More than Just Simple Natural Antioxidants: Oxidative Stress, Aging and Age-Related Diseases. Medicines, 7.","DOI":"10.3390\/medicines7050026"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2020.609274","article-title":"Editorial: Oxidative Stress: How Has It Been Considered in the Design of New Drug Candidates for Neurodegenerative Diseases?","volume":"11","author":"Viegas","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Bhullar, K.S., and Rupasinghe, H.P.V. (2013). Polyphenols: Multipotent therapeutic agents in neurodegenerative diseases. Oxid. Med. Cell. Longev., 2013.","DOI":"10.1155\/2013\/891748"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines9020099","article-title":"Flavonoids: Potential candidates for the treatment of neurodegenerative disorders","volume":"9","author":"Devi","year":"2021","journal-title":"Biomedicines"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/bph.13649","article-title":"Antioxidants from black and green tea: From dietary modulation of oxidative stress to pharmacological mechanisms","volume":"174","author":"Peluso","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Pervin, M., Unno, K., Ohishi, T., Tanabe, H., Miyoshi, N., and Nakamura, Y. (2018). Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. Molecules, 23.","DOI":"10.3390\/molecules23061297"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Essa, M.M., Akbar, M., and Guillemin, G. (2016). The Benefits of Natural Products for Neurodegenerative Diseases, Springer International Publishing. Advances in Neurobiology.","DOI":"10.1007\/978-3-319-28383-8"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Di Paolo, M., Papi, L., Gori, F., and Turillazzi, E. (2019). Natural products in neurodegenerative diseases: A great promise but an ethical challenge. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205170"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Maher, P. (2019). The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123056"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Kabir, M.T., Niaz, K., Jeandet, P., Cl\u00e9ment, C., Mathew, B., Rauf, A., Rengasamy, K.R.R., Sobarzo-S\u00e1nchez, E., and Ashraf, G.M. (2020). Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer\u2019s Disease. Molecules, 25.","DOI":"10.3390\/molecules25061267"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., Orhan, I.E., Banach, M., Rollinger, J.M., Barreca, D., Weckwerth, W., Bauer, R., and Bayer, E.A. (2021). Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov., 2014.","DOI":"10.1038\/s41573-020-00114-z"},{"key":"ref_123","first-page":"5","article-title":"Natural Products and Their Bioactive Compounds: Neuroprotective Potentials against Neurodegenerative Diseases","volume":"2020","author":"Sirajudeen","year":"2020","journal-title":"Evidence-based Complement. Altern. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1007\/s00018-018-2872-2","article-title":"Inhibition of protein misfolding and aggregation by natural phenolic compounds","volume":"75","author":"Dhouafli","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acschemneuro.0c00381","article-title":"Potential Role of Natural Polyphenols against Protein Aggregation Toxicity: In Vitro, In Vivo, and Clinical Studies","volume":"11","author":"Gomez","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Fukutomi, R., Ohishi, T., Koyama, Y., Pervin, M., Nakamura, Y., and Isemura, M. (2021). Beneficial Effects of Epigallocatechin-3-O-Gallate, Chlorogenic Acid, Resveratrol, and Curcumin on Neurodegenerative Diseases. Molecules, 26.","DOI":"10.3390\/molecules26020415"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.neuro.2009.08.013","article-title":"Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation","volume":"30","author":"Feng","year":"2009","journal-title":"Neurotoxicology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jmb.2012.01.013","article-title":"Structural properties of EGCG-induced, nontoxic Alzheimer\u2019s disease A\u03b2 oligomers","volume":"421","author":"Fink","year":"2012","journal-title":"J. Mol. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/cn3001203","article-title":"Curcumin modulates \u03b1-synuclein aggregation and toxicity","volume":"4","author":"Singh","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acschemneuro.5b00214","article-title":"Curcumin Attenuates Amyloid-\u03b2 Aggregate Toxicity and Modulates Amyloid-\u03b2 Aggregation Pathway","volume":"7","author":"Thapa","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-18349-z","article-title":"EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the \u201cActive Oligomer\u201d of \u03b1-Synuclein","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.crbiot.2020.10.002","article-title":"Insights from nature: A review of natural compounds that target protein misfolding in vivo","volume":"2","author":"Terry","year":"2020","journal-title":"Curr. Res. Biotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chembiol.2012.02.003","article-title":"Protein misfolded oligomers: Experimental approaches, mechanism of formation, and structure-toxicity relationships","volume":"19","author":"Bemporad","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2019.00158","article-title":"Diverse misfolded conformational strains and cross-seeding of misfolded proteins implicated in neurodegenerative diseases","volume":"12","author":"Lim","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","article-title":"Protein transmission in neurodegenerative disease","volume":"16","author":"Peng","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jmb.2006.12.007","article-title":"Early Kinetics of Amyloid Fibril Formation Reveals Conformational Reorganisation of Initial Aggregates","volume":"366","author":"Serrano","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1021\/acs.chemrev.8b00731","article-title":"Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates","volume":"119","author":"Ilie","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"Novel proteinaceous infectious particles cause scrapie","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-genet-110711-155524","article-title":"Biology and Genetics of Prions Causing Neurodegeneration","volume":"47","author":"Prusiner","year":"2013","journal-title":"Annu. Rev. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-160361","article-title":"Protein misfolding in prion and prion-like diseases: Reconsidering a required role for protein loss-of-function","volume":"54","author":"Leighton","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/nan.12592","article-title":"Invited Review: The role of prion-like mechanisms in neurodegenerative diseases","volume":"46","author":"Jaunmuktane","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2019.00262","article-title":"Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis","volume":"12","author":"McAlary","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/WCO.0000000000000672","article-title":"The prion-like propagation hypothesis in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"32","author":"Duyckaerts","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-071714-033828","article-title":"Neurodegenerative Diseases: Expanding the Prion Concept","volume":"38","author":"Walker","year":"2015","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejmech.2019.01.045","article-title":"Toward the discovery and development of effective modulators of \u03b1-synuclein amyloid aggregation","volume":"167","author":"Oliveri","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2020.619667","article-title":"Natural Compounds as Inhibitors of A\u03b2 Peptide Aggregation: Chemical Requirements and Molecular Mechanisms","volume":"14","author":"Pagano","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature \u03b1-synuclein and amyloid-\u03b2 fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci. US.A"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","article-title":"How epigallocatechin gallate can inhibit \u03b1-synuclein oligomer toxicity in vitro","volume":"289","author":"Lorenzen","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.febslet.2014.11.026","article-title":"The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios","volume":"589","author":"Wobst","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"32508","DOI":"10.1039\/C7RA03752J","article-title":"The green tea polyphenol (-)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of \u03b1-synuclein, and protects PC12 cells against \u03b1-synuclein-induced toxicity","volume":"7","author":"Zhao","year":"2017","journal-title":"RSC Adv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00775-014-1131-8","article-title":"The hairpin conformation of the amyloid \u03b2 peptide is an important structural motif along the aggregation pathway Topical Issue in honor of Ivano Bertini Guest editors: Lucia Banci, Claudio Luchinat","volume":"19","author":"Abelein","year":"2014","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nlm.2011.08.003","article-title":"The A\u03b2 oligomer hypothesis for synapse failure and memory loss in Alzheimer\u2019s disease","volume":"96","author":"Ferreira","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2019.00319","article-title":"Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies","volume":"12","author":"Galzitskaya","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/pro.3906","article-title":"Progress toward Alzheimer\u2019s disease treatment: Leveraging the Achilles\u2019 heel of A\u03b2 oligomers?","volume":"29","author":"Fantini","year":"2020","journal-title":"Protein Sci."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Longhena, F., Faustini, G., Spillantini, M.G., and Bellucci, A. (2019). Living in promiscuity: The multiple partners of alpha-synuclein at the synapse in physiology and pathology. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010141"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"\u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","article-title":"\u03b1-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer","volume":"287","author":"Fauvet","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature16531","article-title":"Structural disorder of monomeric \u03b1-synuclein persists in mammalian cells","volume":"530","author":"Theillet","year":"2016","journal-title":"Nature"},{"key":"ref_161","first-page":"S53","article-title":"The Synucleinopathies: Twenty Years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/jnc.14965","article-title":"Synucleinopathies: Where we are and where we need to go","volume":"153","author":"Gerhardt","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_163","first-page":"229","article-title":"Emerging concepts in synucleinopathies","volume":"36","author":"Outeiro","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10030391","article-title":"Targeting \u03b1-synuclein for PD Therapeutics: A Pursuit on All Fronts","volume":"10","author":"Teil","year":"2020","journal-title":"Biomolecules"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Ghiglieri, V., Calabrese, V., and Calabresi, P. (2018). Alpha-synuclein: From early synaptic dysfunction to neurodegeneration. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00295"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: From structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/jnc.13249","article-title":"Structure, function and toxicity of alpha-synuclein: The Bermuda triangle in synucleinopathies","volume":"139","author":"Outeiro","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","article-title":"A-Synuclein, Especially the Parkinson\u2019S Disease-Associated Mutants, Forms Pore-Like Annular and Tubular Protofibrils","volume":"322","author":"Lashuel","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/418291a","article-title":"Neurodegenerative disease: Amyloid pores from pathogenic mutations","volume":"418","author":"Lashuel","year":"2002","journal-title":"Nature"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1742-4658.2012.08489.x","article-title":"Role of \u03b1-synuclein penetration into the membrane in the mechanisms of oligomer pore formation","volume":"279","author":"Tsigelny","year":"2012","journal-title":"FEBS J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0024-3205(01)01438-2","article-title":"Il The green tea polyphenol (-)-epigallocatechin gallate attenuates \u03b2-amyloid-induced neurotoxicity in cultured hippocampal neurons","volume":"70","author":"Choi","year":"2001","journal-title":"Life Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cellbi.2007.08.007","article-title":"Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) on paraquat-induced apoptosis in PC12 cells","volume":"32","author":"Hou","year":"2008","journal-title":"Cell Biol. Int."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/WNR.0b013e32830b8ae1","article-title":"Epigallocatechin-3 -gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation","volume":"19","author":"Shimmyo","year":"2008","journal-title":"Neuroreport"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/JAD-2009-1048","article-title":"(-)-epigallocatechin-3-gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through stat3 activation","volume":"17","author":"Wang","year":"2009","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12272-009-1609-z","article-title":"Neuroprotective effect of epigallocatechin-3-gallate against \u03b2-amyloid-induced oxidative and nitrosative cell death via augmentation of antioxidant defense capacity","volume":"32","author":"Kim","year":"2009","journal-title":"Arch. Pharm. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neurobiolaging.2007.05.012","article-title":"Epigallocatechin gallate (EGCG) suppresses \u03b2-amyloid-induced neurotoxicity through inhibiting c-Abl\/FE65 nuclear translocation and GSK3\u03b2 activation","volume":"30","author":"Lin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-009-0284-z","article-title":"Effects of epigallocatechin gallate on rotenone-injured murine brain cultures","volume":"117","author":"Moldzio","year":"2010","journal-title":"J. Neural Transm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2010.06.018","article-title":"(-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells","volume":"482","author":"Tai","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6882-12-82","article-title":"Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1\/PGC-1\u03b1 signaling pathway","volume":"12","author":"Ye","year":"2012","journal-title":"BMC Complement. Altern. Med."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Chen, D., Kanthasamy, A.G., and Reddy, M.B. (2015). EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model. Parkinsons. Dis., 2015.","DOI":"10.1155\/2015\/843906"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2015.11.048","article-title":"Epigallocatechin gallate attenuates amyloid \u03b2-induced inflammation and neurotoxicity in EOC 13.31 microglia","volume":"770","author":"Huang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules24162940","article-title":"Complex of EGCG with Cu(II) suppresses amyloid aggregation and Cu(II)-induced cytotoxicity of \u03b1-synuclein","volume":"24","author":"Teng","year":"2019","journal-title":"Molecules"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","article-title":"Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice","volume":"25","author":"Shytle","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_185","first-page":"237","article-title":"The beneficial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer\u2019s disease in rat: A behavioral analysis","volume":"11","author":"Rasoolijazi","year":"2007","journal-title":"Iran. Biomed. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.brainres.2008.02.107","article-title":"Green tea epigallocatechin-3-gallate (EGCG) reduces \u03b2-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice","volume":"1214","author":"Arendash","year":"2008","journal-title":"Brain Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2008.10.012","article-title":"(-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency","volume":"1250","author":"Lee","year":"2009","journal-title":"Brain Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3945\/jn.109.109785","article-title":"Green tea (-)-epigallocatechin-3-gallate inhibits \u03b2-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-\u03baB pathways in mice","volume":"139","author":"Lee","year":"2009","journal-title":"J. Nutr."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1248\/bpb.32.55","article-title":"Neuroprotective effects of (-)-epigallocatechin-3-gallate on aging mice induced by D-galactose","volume":"32","author":"He","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jnutbio.2012.06.011","article-title":"Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties","volume":"24","author":"Lee","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbr.2012.08.039","article-title":"Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia","volume":"236","author":"Biasibetti","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-140981","article-title":"Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer\u2019s disease mouse model","volume":"44","author":"Walker","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yexcr.2015.04.004","article-title":"(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer\u2019s disease model mice by upregulating neprilysin expression","volume":"334","author":"Chang","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WNR.0000000000000803","article-title":"(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer\u2019s disease","volume":"28","author":"Guo","year":"2017","journal-title":"Neuroreport"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2018.00244","article-title":"EGCG nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of Alzheimer\u2019s disease","volume":"10","author":"Singh","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mnfr.201700890","article-title":"Epigallocatechin Gallate Reduces Amyloid \u03b2-Induced Neurotoxicity via Inhibiting Endoplasmic Reticulum Stress-Mediated Apoptosis","volume":"62","author":"Du","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1074\/jbc.RA118.004280","article-title":"Combined treatment with the phenolics ()-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice","volume":"294","author":"Mori","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","article-title":"Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)\/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe\/PS1dE9 Alzheimer\u2019s disease mice model","volume":"301","author":"Cano","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s12035-019-01849-6","article-title":"Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe\/PS1dE9 Mice","volume":"57","author":"Ettcheto","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"104382","DOI":"10.1016\/j.bioorg.2020.104382","article-title":"Inhibition of A\u03b2 aggregates in Alzheimer\u2019s disease by epigallocatechin and epicatechin-3-gallate from green tea","volume":"105","author":"Chen","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2001.00490.x","article-title":"Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration","volume":"78","author":"Levites","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0161-813X(02)00079-7","article-title":"Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s disease in mice by tea phenolic epigallocatechin 3-gallate","volume":"23","author":"Choi","year":"2002","journal-title":"Neurotoxicology"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Bitu Pinto, N., Da Silva Alexandre, B., Neves, K.R.T., Silva, A.H., Leal, L.K.A.M., and Viana, G.S.B. (2015). Neuroprotective Properties of the Standardized Extract from Camellia sinensis (Green Tea) and Its Main Bioactive Components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA Model of Parkinson\u2019s Disease. Evidence-based Complement. Altern. Med., 2015.","DOI":"10.1155\/2015\/161092"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3945\/jn.117.255034","article-title":"Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease","volume":"147","author":"Xu","year":"2017","journal-title":"J. Nutr."},{"key":"ref_205","first-page":"4883","article-title":"(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson\u2019s disease","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1096\/fj.201903125RR","article-title":"EGCG ameliorates neuronal and behavioral defects by remodeling gut microbiota and TotM expression in Drosophila models of Parkinson\u2019s disease","volume":"34","author":"Xu","year":"2020","journal-title":"FASEB J."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12640-019-00143-6","article-title":"Protective Effect of (\u2212)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats","volume":"37","author":"Tseng","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11064-006-9166-z","article-title":"Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"31","author":"Xu","year":"2006","journal-title":"Neurochem. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neulet.2005.10.056","article-title":"The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice","volume":"395","author":"Koh","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.fct.2009.07.011","article-title":"Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: A novel nitric oxide mechanism","volume":"47","author":"Kumar","year":"2009","journal-title":"Food Chem. Toxicol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1371\/journal.pone.0029933","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \u201cIn vivo\u201d evidence from FAP mice models","volume":"7","author":"Ferreira","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","article-title":"Inhibition and disaggregation of \u03b1-synuclein oligomers by natural polyphenolic compounds","volume":"585","author":"Caruana","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/ja3115696","article-title":"Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils","volume":"135","author":"Palhano","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1002\/chem.201403188","article-title":"Natural compounds against neurodegenerative diseases: Molecular characterization of the interaction of catechins from green tea with A\u03b21-42, PrP106-126, and ataxin-3 oligomers","volume":"20","author":"Sironi","year":"2014","journal-title":"Chem. A Eur. J."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acschemneuro.7b00261","article-title":"Comparison of \u03b1-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors","volume":"8","author":"Jha","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"13720","DOI":"10.1021\/jacs.7b05012","article-title":"Molecular mechanism for the (-)-Epigallocatechin gallate-induced toxic to nontoxic remodeling of A\u03b2 oligomers","volume":"139","author":"Ahmed","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1039\/C9SC01331H","article-title":"Atomic resolution map of the soluble amyloid beta assembly toxic surfaces","volume":"10","author":"Ahmed","year":"2019","journal-title":"Chem. Sci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"21497","DOI":"10.1021\/acsomega.0c02063","article-title":"Distinguishing the Effect on the Rate and Yield of A\u03b242 Aggregation by Green Tea Polyphenol EGCG","volume":"5","author":"Park","year":"2020","journal-title":"ACS Omega"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1021\/acsbiomaterials.0c00188","article-title":"Green Tea Polyphenol Microparticles Based on the Oxidative Coupling of EGCG Inhibit Amyloid Aggregation\/Cytotoxicity and Serve as a Platform for Drug Delivery","volume":"6","author":"Fernandes","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1021\/tx960130e","article-title":"\u03b2-amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer\u2019s disease","volume":"10","author":"Butterfield","year":"1997","journal-title":"Chem. Res. Toxicol."},{"key":"ref_221","first-page":"325","article-title":"In vitro and in vivo oxidative stress associated with Alzheimer\u2019s amyloid \u03b2-peptide (1-42)","volume":"20","author":"Yatin","year":"1999","journal-title":"Neurobiol. Aging"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1006\/jsbi.2000.4274","article-title":"Review: Alzheimer\u2019s amyloid \u03b2-peptide-associated free radical oxidative stress and neurotoxicity","volume":"130","author":"Varadarajan","year":"2000","journal-title":"J. Struct. Biol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/nbdi.2002.0515","article-title":"Oxidative stress increases expression and activity of BACE in NT2 neurons","volume":"10","author":"Tamagno","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Maia, M.A., and Sousa, E. (2019). BACE-1 and \u03b3-secretase as therapeutic targets for Alzheimer\u2019s disease. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010041"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arr.2013.10.002","article-title":"The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer\u2019s disease animal model","volume":"13","author":"Cheng","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson\u2019s disease: Animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson\u2019s Disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/ejcn.2017.89","article-title":"Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women","volume":"71","author":"Most","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1021\/acs.jafc.0c03587","article-title":"Reciprocal Interactions between Epigallocatechin-3-gallate (EGCG) and Human Gut Microbiota in Vitro","volume":"68","author":"Liu","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Zhu, F., Li, C., Chu, F., Tian, X., and Zhu, J. (Front. Aging Neurosci., 2020). Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer \u2019 s Disease, Front. Aging Neurosci.","DOI":"10.3389\/fnagi.2020.544235"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"110112","DOI":"10.1016\/j.pnpbp.2020.110112","article-title":"Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer\u2019s disease","volume":"106","author":"Goyal","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","article-title":"Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): A randomised, double-blind, placebo-controlled trial","volume":"18","author":"Levin","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Silva, C., Pinto, M., Fernandes, C., Benfeito, S., and Borges, F. (2021). Antioxidant Therapy and Neurodegenerative Disorders: Lessons From Clinical Trials, Elsevier Inc.","DOI":"10.1016\/B978-0-12-801238-3.11611-3"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/molecules23092346","article-title":"Bioavailability of tea catechins and its improvement","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/jf0519055","article-title":"Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions","volume":"53","author":"Sang","year":"2005","journal-title":"J. Agric. Food Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/ja311374b","article-title":"Biocompatible, functional spheres based on oxidative coupling assembly of green tea polyphenols","volume":"135","author":"Chen","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1021\/bi3012548","article-title":"Alternative pathways of human islet amyloid polypeptide aggregation distinguished by 19F nuclear magnetic resonance-detected kinetics of monomer consumption","volume":"51","author":"Suzuki","year":"2012","journal-title":"Biochemistry"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2017.07.009","article-title":"mei Comparison of disaggregative effect of A-type EGCG dimer and EGCG monomer on the preformed bovine insulin amyloid fibrils","volume":"230","author":"Nie","year":"2017","journal-title":"Biophys. Chem."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Roy, D., Bhattacharyya, D., and Bhunia, A. (2019). Do catechins (ECG and EGCG)bind to the same site as thioflavin T (ThT) in amyloid fibril? Answer from saturation transfer difference NMR. Nat. Prod. Commun., 14.","DOI":"10.1177\/1934578X19849791"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Kelley, M., Sant\u2019Anna, R., Fernandes, L., and Palhano, F.L. (2021). Pentameric Thiophene as a Probe to Monitor EGCG\u2019s Remodeling Activity of Mature Amyloid Fibrils: Overcoming Signal Artifacts of Thioflavin T. ACS Omega.","DOI":"10.1021\/acsomega.1c00680"},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Sternke-Hoffmann, R., Peduzzo, A., Bolakhrif, N., Haas, R., and Buell, A.K. (2020). The aggregation conditions define whether EGCG is an inhibitor or enhancer of \u03b1-synuclein amyloid fibril formation. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202002.0018.v1"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/cb1001203","article-title":"ANS binding reveals common features of cytotoxic amyloid species","volume":"5","author":"Bolognesi","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"24765","DOI":"10.1074\/jbc.M111.329763","article-title":"Conformational differences between two amyloid \u03b2oligomers of similar size and dissimilar toxicity","volume":"287","author":"Ladiwala","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1039\/C3CS60431D","article-title":"Differences between amyloid-\u03b2 aggregation in solution and on the membrane: Insights into elucidation of the mechanistic details of Alzheimer\u2019s disease","volume":"43","author":"Kotler","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-36700-w","article-title":"Structural features distinguishing infectious ex vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro","volume":"9","author":"Terry","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12683-8","article-title":"Cryo-EM structure and polymorphism of A\u03b2 amyloid fibrils purified from Alzheimer\u2019s brain tissue","volume":"10","author":"Kollmer","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/5\/767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:05:01Z","timestamp":1760162701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/5\/767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":248,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["biom11050767"],"URL":"https:\/\/doi.org\/10.3390\/biom11050767","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]}}}